2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
59
Carcinoma, Hepatocellular
46
Colorectal Neoplasms
33
Stomach Neoplasms
31
Esophageal Squamous Cell Carcinoma
27
Squamous Cell Carcinoma of Head and Neck
20
Esophageal Neoplasms
14
Small Cell Lung Carcinoma
13
Neoplasm Metastasis
13
Lung Neoplasms
13
Rectal Neoplasms
12
Head and Neck Neoplasms
12
Advanced Solid Tumor
12
Triple Negative Breast Neoplasms
11
Cholangiocarcinoma
11
Nasopharyngeal Carcinoma
10
Melanoma
10
Uterine Cervical Neoplasms
9
Recurrence
9
Neoplasms
9
Colonic Neoplasms
9
Pancreatic Neoplasms
7
Urinary Bladder Neoplasms
6
Solid Tumor
6
Carcinoma, Transitional Cell
6
Breast Neoplasms
6
Sarcoma
5
Lymphoma, Extranodal NK-T-Cell
5
Lymphoma
5
Hodgkin Disease
5
Interventions
Cisplatin
57
Pemetrexed
46
pembrolizumab
18
Nivolumab
15
Carboplatin
15
Gemcitabine
14
Cyclophosphamide
13
Radiotherapy
10
Drug Therapy
9
atezolizumab
8
Platinum
7
Ipilimumab
7
Doxorubicin
7
durvalumab
6
1,2-diaminocyclohexaneplatinum II citrate
6
tremelimumab
5
sodium thiosulfate
5
Vinorelbine
5
Radiotherapy, Intensity-Modulated
5
Interleukin-2
5
Chemotherapy, Adjuvant
5
Cerebral Decortication
5
sargramostim
4
fludarabine
4
defactinib
4
aldesleukin
4
tumor necrosis factor-alpha, CNGRC fusion protein, human
3
cediranib
3
Photochemotherapy
3
Neoadjuvant Therapy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mesothelioma, Malignant
×
tislelizumab
×
Clear all
NCT05582031
2023-06-07
REFIT-MSS
Translational Research in Oncology
Phase 2
Withdrawn